var data={"title":"Nitazoxanide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitazoxanide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6657?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">see &quot;Nitazoxanide: Drug information&quot;</a> and <a href=\"topic.htm?path=nitazoxanide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitazoxanide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201754\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alinia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048945\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiprotozoal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048938\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">see &quot;Nitazoxanide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> For doses &lt;500 mg, the oral suspension should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptosporidiosis</b>\n      <i>\n        <b> (Cryptosporidium parvum)</b></i>: <b>Note:</b> In non-HIV patients, usual treatment duration is 3 days (<i>Red Book</i> [AAP 2015]). In HIV-exposed/-positive patients, consistently effective treatment options are lacking; the suggested treatment duration is 3 to 14 days in conjunction with optimized combination antiretroviral therapy (HHS [OI pediatric 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 3 years: Oral: 100 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: Oral: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Fasciola hepatica</b></i>\n      <b> (sheep liver fluke)</b> (<i>Red Book</i> [AAP 2015]): Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 3 years: Oral: 100 mg every 12 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: Oral: 200 mg every 12 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: 500 mg every 12 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Giardiasis (<i>Giardia intestinalis/lamblia/duodenalis</i>)</b>\n      <b>; regardless of HIV-status (HHS </b>\n      <b>[OI </b>\n      <b>pediatric </b>\n      <b>2013], <i>Red Book</i> [AAP 2015</b>\n      <b>]</b>\n      <b>):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 3 years: Oral: 100 mg every 12 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: Oral: 200 mg every 12 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: 500 mg every 12 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Hymenolepis nana</b></i>\n      <b> (dwarf tapeworm): </b>Limited data available (CDC 2012; <i>Red</i><i> Book</i> [AAP 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 3 years: 100 mg twice daily for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: 200 mg twice daily for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: 500 mg twice daily for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza; a</b>\n      <b>cute uncomplicated: </b>Limited data available: Children &ge;12 years and Adolescents: Oral: 600 mg twice daily for 5 days; in a double-blind, placebo controlled trial of 624 subjects (age range: 12 to 65 years), a 5-day course was reported to shorten the duration of symptoms (Haffizulla 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Diarrhea, infectious caused by <i>Cryptosporidium parvum</i> or <i>Giardia lamblia</i>:</b> Oral suspension or tablets: 500 mg every 12 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201736\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alinia: 100 mg/5 mL (60 mL) [contains fd&amp;c red #40, sodium benzoate; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alinia: 500 mg [contains corn starch, fd&amp;c blue #2 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake, soybean lecithin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201725\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048948\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Minimize gastric irritation by administering with food; shake suspension well prior to administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201750\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Following reconstitution of oral suspension, discard unused portion after 7 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048947\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Treatment of diarrhea caused by <i>Giardia lamblia</i> or <i>Cryptosporidium parvum</i> in immunocompetent patients (FDA approved in ages &ge;1 year and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Treatment of diarrhea caused by <i>Giardia lamblia</i> or <i>Cryptosporidium parvum</i> in immunocompetent patients (FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used for the treatment of dwarf tapeworm, fluke (sheep liver fluke) infections, and to reduce duration of symptoms with acute uncomplicated influenza</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201775\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Diarrhea (exacerbation), dizziness, dyspnea, gastroesophageal reflux disease, skin rash, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201741\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to nitazoxanide or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201728\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: Nitazoxanide had not been studied for treatment of diarrhea caused by <i>G. lamblia</i> in patients with HIV infection. Nitazoxanide has not been shown to be superior to placebo for treatment of diarrhea caused by <i>C. parvum</i> in HIV-infected patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunocompromised patients: Nitazoxanide had not been studied for treatment of diarrhea caused by <i>G. lamblia</i> in patients with immunodeficiency. Nitazoxanide has not been shown to be superior to placebo for treatment of diarrhea caused by <i>C. parvum</i> in patients with immunodeficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299763\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221927\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12904&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201751\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food increases AUC. Management: Take with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201742\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Human data is not available; however, nitazoxanide may be used during pregnancy after the first trimester in women with severe symptoms of cryptosporidiosis (HHS [opportunistic; adult] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048944\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic liver function tests, stool frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201727\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nitazoxanide is rapidly metabolized to the active metabolite tizoxanide <i>in vivo</i>. Activity may be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism. <i>In vitro</i>, nitazoxanide and tizoxanide inhibit the growth of sporozoites and oocysts of <i>Cryptosporidium parvum</i> and trophozoites of <i>Giardia lamblia</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201740\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In pediatric patients (1-18 years of age), pharmacokinetic properties similar to adult when dosed equivalently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Tizoxanide: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Relative bioavailability of suspension compared to tablet: 70%; tablet and suspension are not bioequivalent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Tizoxanide: 1 to 1.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, to an active metabolite, tizoxanide. Tizoxanide undergoes conjugation to form tizoxanide glucuronide. Nitazoxanide is not detectable in the serum following oral administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Tizoxanide and tizoxanide glucuronide: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~33%); feces (~67%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048952\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">The oral suspension contains sucrose 1.48 g/5 mL. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422268\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Alinia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (60 mL): $626.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Alinia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (12): $1,483.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539902\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adnix (BD);</li>\n      <li>Anelmin (PY);</li>\n      <li>Annita (BR);</li>\n      <li>Celectan (CO, VE);</li>\n      <li>Colufase (EC, PE);</li>\n      <li>Coluquim (PE);</li>\n      <li>Daxon (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Dexidex (MX);</li>\n      <li>Diar (BD);</li>\n      <li>Diasis (BD);</li>\n      <li>Givotan (PY);</li>\n      <li>Heliton (AR);</li>\n      <li>Kidonax (MX);</li>\n      <li>Nidozox (BD);</li>\n      <li>Nitalet (BD);</li>\n      <li>Nitarid (IN);</li>\n      <li>Noxom (PY);</li>\n      <li>Pacovanton (MX);</li>\n      <li>Paramix (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alinia tablets and oral suspension (nitazoxanide) [prescribing information]. Tampa, FL: Romark Lc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). &quot;Drugs for Parasitic Infections.&quot; In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Parasites - Hymenolepiasis (also known as Hymenolepis nana infection). Available at <a href=\"https://www.cdc.gov/parasites/hymenolepis/health_professionals/index.html\" target=\"_blank\">https://www.cdc.gov/parasites/hymenolepis/health_professionals/index.html</a>. Accessed January 17, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. <i>Lancet Infect Dis</i>. 2014;14(7):609-618.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitazoxanide-pediatric-drug-information/abstract-text/24852376/pubmed\" target=\"_blank\" id=\"24852376\">24852376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. December 2016. Available at <a href=\"https://aidsinfo.nih.gov/guidelines/html/5/pediatric-opportunistic-infection/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/5/pediatric-opportunistic-infection/0</a>. Accessed October 8, 2017</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2017</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12904 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201754\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048945\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048938\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201736\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F201725\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048948\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F201750\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048947\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201775\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201741\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201728\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299763\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221927\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F201751\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F201742\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048944\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201727\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F201740\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1048952\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422268\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539902\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12904|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">Nitazoxanide: Drug information</a></li><li><a href=\"topic.htm?path=nitazoxanide-patient-drug-information\" class=\"drug drug_patient\">Nitazoxanide: Patient drug information</a></li></ul></div></div>","javascript":null}